NCBiotech News

Dallas-based Taysha Gene Therapies announced plans today to invest $75 million in a gene therapy manufacturing facility in Durham that will employ 201 people over the next three years.

Durham's BioSkryb is launching a grant program to secure a “breakthrough” in single-cell genomics using its proprietary technology, recently launched commercially as ResolveDNA.

The FDA has approved a once-daily capsule developed by Durham's BioCryst Pharmaceuticals to prevent the life-threatening attacks of swelling in people with the rare disease called hereditary angioedema, or HAE.

Eli Lilly and Durham gene editing innovator Precision Biosciences announced a research collaboration and exclusive license agreement that could potentially be worth over $2.7 billion.

Morrisville-based Locus Biosciences has signed an agreement with a global non-profit to help fund a new CRISPR Cas3 antibacterial therapy to treat recurrent urinary tract infections.

Pfizer announced today that it will invest an additional $500 million and add 300 more jobs to increase its newly completed gene therapy manufacturing capabilities at its 230-acre campus in Sanford, North Carolina.

Gene therapy pioneer AskBio of Chapel Hill, supported in its early years by NCBiotech, will be acquired by Bayer AG, the German healthcare and ag conglomerate, for up to $4 billion.

The innovative California-based cancer-detection company GRAIL, Inc., which is establishing a $100 million-plus facility in Research Triangle Park, is preparing to go public.

Novartis has renamed its previously acquired AveXis gene therapy arm. It's now called Novartis Gene Therapies.

bluebird bio, a global gene therapy company with a new manufacturing facility in Durham, has unveiled positive results in clinical trials of its treatment for boys with a rare and deadly neurological disorder.

Leading life sciences magazine PharmaVoice has named three North Carolina executives to its list of the 100 most inspiring leaders in the pharmaceutical industry.

A young Boston-area gene therapy company, Beam Therapeutics, has joined a cluster of gene and cell therapy startups with plans to build an $83 million biomanufacturing facility in Durham that could employ more than 200 people over five years.

The rapid global march of the coronavirus that began in Wuhan, China several months ago could be slowed by researchers and biotech firms 7,770 miles away – in the Research Triangle of North Carolina.

Jude Samulski, a UNC gene therapy pioneer, has been awarded an international patent application by the World Intellectual Property Organization for his regulated gene-editing system.

Audentes Therapeutics, a San Francisco company whose name changed to Astellas Gene Therapies on March 31, 2021, announced plans for a $109.4 million, 209-employee gene therapy production facility in Sanford, a short distance from a $600 million Pfizer gene therapy campus under construction.